CAS 925701-49-1
:KU-60019
- (2R,6S)-2,6-Dimethyl-N-[5-[6-(4-morpholinyl)-4-oxo-4H-pyran-2-yl]-9H-thioxanthen-2-yl]-4-morpholineacetamide
- 2-[(2R,6S)-2,6-Dimethyl-4-morpholinyl]-N-{5-[6-(4-morpholinyl)-4-oxo-4H-pyran-2-yl]-9H-thioxanthen-2-yl}acetamide
(2R,6S)-Rel-2,6-Dimethyl-N-[5-[6-(4-Morpholinyl)-4-Oxo-4H-Pyran-2-Yl]-9H-Thioxanthen-2-Yl]-4-Morpholineacetamide
CAS:(2R,6S)-Rel-2,6-Dimethyl-N-[5-[6-(4-Morpholinyl)-4-Oxo-4H-Pyran-2-Yl]-9H-Thioxanthen-2-Yl]-4-MorpholineacetamidePureza:98%Peso molecular:547.68g/molKU60019
CAS:Ku-60019 is a potent, reversible inhibitor of ATM kinase (IC50: 6.3 nM). It is much less effective or without effect against a panel of 229 other kinases.Fórmula:C30H33N3O5SPureza:95.9% - 99.7%Forma y color:SolidPeso molecular:547.67KU-60019
CAS:KU-60019 is a potent and selective inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase. KU-60019 blocks the activation of EGFR and other signaling pathways, which may be involved in the pathogenesis of autoimmune diseases, cancer and metabolic disorders. KU-60019 inhibits cellular proliferation by inhibiting tyrosine phosphorylation in the EGFR pathway. In addition, KU-60019 also inhibits DNA synthesis and cell cycle progression by targeting other intracellular targets such as cyclin D1, CDK4, CDK6 and p27. The chemical structure of KU-60019 is similar to that of imatinib mesylate, an inhibitor for chronic myeloid leukemia that has been approved by the FDA for treatment. However, unlike imatinib mesylate, KU-60019 does not inhibit protein kinase C or Raf kinases. Further investigations are needed to determine the mechanism
Fórmula:C30H33N3O5SPureza:Min. 95%Peso molecular:547.67 g/mol



